The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis
Open accessAbstract
Objective: To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)–positive or RF‐negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months. Methods: Between May 2007 and October 2010, a multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of 2 aggressive treatments was conducted in 85 children ages 2–16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months. Results: By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ 2 = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3 patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events. Conclusion: Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent‐onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Self-citationPreliminary definition of improvement in juvenile arthritis
Giannini, E. H., Ruperto, N., Ravelli, A., Lovell, D. J., Felson, D. T., & Martini, A. (1997) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r · Cited by 1,047
Self-citationMeasurement of health status in children with juvenile rheumatoid arthritis
Singh, G., Athreya, B. H., Fries, J. F., & Goldsmith, D. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371209 · Cited by 838
Beukelman, T., Patkar, N. M., Saag, K. G., Tolleson‐Rinehart, S., Cron, R. Q., DeWitt, E. M., Ilowite, N. T., Kimura, Y., Laxer, R. M., Lovell, D. J., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20460 · Cited by 834
Self-citationAdalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Lovell, D. J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., Nemcova, D., Mouy, R., Sandborg, C., Bohnsack, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706290 · Cited by 625
Self-citationPreliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
Wallace, C. A., Ruperto, N., & Giannini, E. H. (2004) · PubMed · Cited by 623
Self-citationWallace, C. A., Giannini, E. H., Huang, B., Itert, L., Ruperto, N., Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG), & Paediatric Rheumatology International Trials Organisation (PRINTO) (2011) · Arthritis Care & Research · doi:10.1002/acr.20497 · Cited by 574
Self-citationRuperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio-Pérez, N., Silva, C. A., Abud-Mendoza, C., Burgos-Vargas, R., Gerloni, V., Melo-Gomes, J. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60998-8 · Cited by 560
Self-citationFactors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
Anderson, J. J., Wells, G., Verhoeven, A. C., & Felson, D. T. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<22::aid-anr4>3.0.co;2-9 · Cited by 503
Lovell, D. J., Reiff, A. O., Ilowite, N. T., Wallace, C. A., Chon, Y., Lin, S., Baumgartner, S. W., Giannini, E. H., & Pediatric Rheumatology Collaborative Study Group (2008) · Arthritis & Rheumatism · doi:10.1002/art.23427 · Cited by 324
Self-citationChronic Childhood Disorders: Prevalence and Impact
Gortmaker, S. L., & Sappenfield, W. (1984) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)34532-1 · Cited by 299
Foell, D. (2010) · JAMA · doi:10.1001/jama.2010.375 · Cited by 291
Treating rheumatoid arthritis early: A window of opportunity?
O'Dell, J. R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10092 · Cited by 266
Quinn, M. A., & Emery, P. (2003) · PubMed · Cited by 213
Understanding the window of opportunity concept in early rheumatoid arthritis
Boers, M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11156 · Cited by 180
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis.
Bowyer, S. L., Roettcher, P. A., Higgins, G. C., Adams, B. S., Myers, L. K., Wallace, C. A., Rennebohm, R. M., Moore, T. L., Pepmueller, P. H., Spencer, C. H., et al. (2003) · PubMed · Cited by 117
Self-citationMagni‐Manzoni, S., Rossi, F., Pistorio, A., Temporini, F., Viola, S., Beluffi, G., Martini, A., & Ravelli, A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11337 · Cited by 102
Žák, M., Hassager, C., Lovell, D. J., Nielsen, S., Henderson, C. J., & Pedersen, F. K. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199904)42:4<790::aid-anr24>3.0.co;2-g · Cited by 92
Self-citationMalattia, C., Damasio, M. B., Pistorio, A., Ioseliani, M., Vilca, I., Valle, M., Ruperto, N., Viola, S., Buoncompagni, A., Magnano, G. M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.126862 · Cited by 76
Rheumatic Diseases of Childhood
Singsen, B. H. (1990) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00889-9 · Cited by 64
Duffy, C. M. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.01.009 · Cited by 55
Saxena, N., Aggarwal, A., & Misra, R. (2005) · PubMed · Cited by 53
Remission in Juvenile Idiopathic Arthritis: Current Facts
Shenoi, S., & Wallace, C. A. (2010) · Current Rheumatology Reports · doi:10.1007/s11926-010-0085-2 · Cited by 27
Self-citationDuffy, C. M. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.07.003 · Cited by 24
Cited by
Ringold, S., Angeles‐Han, S. T., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Ferguson, P. J., Gewanter, H., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23870 · Cited by 462
Self-citationJuvenile Idiopathic Arthritis: Will Etanercept be an Improvement over Current Therapies?
De Benedetti, F., & Ravelli, A. (2000) · BioDrugs · doi:10.2165/00063030-200014020-00003 · Cited by 428
Martini, A., Lovell, D. J., Albani, S., Brunner, H. I., Hyrich, K. L., Thompson, S. D., & Ruperto, N. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00332-8 · Cited by 289
Self-citationEfficacy of high-dose methotrexate in pediatric non-infectious uveitis
Wieringa, W. G., Armbrust, W., Legger, G. E., & Los, L. I. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2018.1529800 · Cited by 17
Metadata
- Authors
- Wallace, C. A., Giannini, E. H., Spalding, S. J., Hashkes, P. J., O'Neil, K. M., Zeft, A. S., Szer, I. S., Ringold, S., Brunner, H. I., Schanberg, L. E., Sundel, R. P., Milojevic, D., Punaro, M. G., Chira, P., Gottlieb, B. S., Higgins, G. C., Ilowite, N. T., Kimura, Y., Hamilton, S., Johnson, A., Huang, B., Lovell, D. J., & for the Childhood Arthritis and Rheumatology Research Alliance
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-05-25
- Volume
- 64
- Issue
- 6
- Pages
- 2012-2021
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2014383245
- Cited by
- 312
- References
- 25
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.